Proteomics International Laboratories - PromarkerD Demonstrates Predictive Value for Diabetic Kidney Disease in Aboriginal Australians - May be time to get on this Horse.
- Noel Ong
- 2 days ago
- 5 min read
Announcement
PromarkerD predicts risk of DKD in Aboriginal Australians - 15 December 2025 (click here to view the announcement)
Proteomics International Laboratories Ltd (ASX: PIQ) has released new clinical evidence demonstrating that its PromarkerD blood test (Figure 1) has meaningful predictive value for diabetic kidney disease (DKD) in Aboriginal Australians, one of the highest-risk populations globally. The findings are based on Australian clinical cohorts and reinforce the test’s relevance in addressing a major national health challenge.
Figure 1: PromarkerD Clinical Pathway (source: PIQ)
Highlights – Clinical Validation of PromarkerD in High-Risk Populations
PromarkerD demonstrated acceptable and clinically meaningful predictive accuracy for DKD in Aboriginal people with diabetes.
A peer-reviewed study published in the Internal Medicine Journal showed no statistically significant difference in test performance between Aboriginal and non-Aboriginal participants.
The test achieved an area under the ROC curve (AUC) of 0.71 in Aboriginal participants, which falls within the range considered clinically acceptable.
High negative predictive values of greater than 85% indicate strong “rule-out” capability, meaning individuals with a low PromarkerD score are unlikely to experience near-term kidney decline.
The study highlights the potential for PromarkerD to support better allocation of healthcare resources by identifying patients who may not require intensive intervention.
National context remains critical, with the burden of diabetic kidney disease reported to be more than seven times higher in Aboriginal people than in non-Indigenous Australians.
The next-generation PromarkerD test is now available to type-2 diabetes patients in Australia through multiple healthcare channels.
Leadership Commentary
Proteomics International Managing Director Dr Richard Lipscombe commented:
“Aboriginal people bear a disproportionately high burden of diabetes and DKD, often with earlier onset and faster progression - raising both the need and the potential benefit for better prognostic tests validated in these communities.”
About Proteomics International Laboratories - The Project
The findings are derived from an analysis of 1,081 adults with diabetes, including 71 Aboriginal participants, sourced from the Fremantle Diabetes Study Phase II and the Aboriginal Diabetes Sub-study. The study assessed PromarkerD’s ability to predict incident DKD or rapid kidney function decline over four years. The results support the test’s role in identifying patients at low risk of progression, enabling more targeted clinical management (Figure 2).
Figure 2: PromarkerD Biomarker Analysis and Risk Classification Workflow (source: PIQ)
Near-term Milestones to Watch
(Figure 3)
Ongoing dissemination and citation of the Internal Medicine Journal publication in clinical and healthcare policy settings.
Continued uptake of the next-generation PromarkerD test across Australian healthcare channels.
Further engagement with clinicians and health services focused on high-risk and underserved populations.
Figure 3: Near-Term Commercial and Clinical Milestones for PromarkerD (source: PIQ)
Samso Concluding Comments
This study adds an important layer of clinical validation for PromarkerD in a population with significant unmet medical needs. The results are grounded in peer-reviewed data rather than promotional claims.
Another value-creating news to PIQ. This has been one of the easiest companies to review as the rising share price since Samso started covering the business is very clear that the business model is working.
As you can see in Figure 4, the marekt seem to be liking the news coming out from PIQ. Our coverage of PIQ started on June 6, 2025 (A Blood Test Revolution in Women’s Health – PromarkerEndo’s Clinical Leap Forward on Endometriosis), and we have been following the journey since.
Figure 4:The PIQ share price as of 31st December 2025. (source: CommSec)
This recent ASX release is a great tick for the company as it tries to tackle one of the most common ailments for the Australian Indigenous people. I have always said that if technology creates a benefit in the medical arena, the business of making money will be automatic, especially with the transition to an increased reliance on technology.
With a market capitalisation of just under AUD $100M, this may be a good horse to ride. The boxes are getting ticked, and the market is liking these boxes being ticked.
The Samso Way – Seek the Research
As always, Samso encourages investors and readers to review the original clinical publication and ASX announcement and form their own view based on the data.
Our mission is simple: cut through the noise and spotlight what matters—genuine stories, grounded insights, and real opportunity.
Our content is well-researched and is only created if the team sees merit in discussing the company or concept. Investors can explore our three core platforms:
There may be numerous paths to success in investing, but the common thread among successful individuals is that they remain committed to making informed decisions. Equip yourself with the right knowledge and tools, and you will be well on your way to achieving your financial goals.
Most importantly, investors need to be absolutely diligent in understanding their own risk-reward tolerance and capabilities. Never bite off more than you can chew. As they say, Rome wasn’t built in a day, and the Great Wall stood because it took centuries to complete.
The Samso Philosophy:
Stay curious. Stay sharp. And remember—digging deeper always uncovers the real value.
In Life, there is no such thing as a Free Lunch.
Happy Investing, and the only four-letter word you need to know is DYOR.
To support our independent nature of our work, please head over to our Support Page and give us a helping hand in any of the ways listed. This is a new initiate for the Samso Platform, and it was always the concept of Samso when we started this journey in 2018.
Disclaimer
The information or opinions provided herein do not constitute investment advice, an offer or solicitation to subscribe for, purchase or sell the investment product(s) mentioned herein. It does not take into consideration, nor have any regard to your specific investment objectives, financial situation, risk profile, tax position and particular, or unique needs and constraints.
Share to Grow: Your Bonus
Samso has just released an eBook: How to Add Value to your Share Portfolio
A lesson on geological models sought by mining companies that gives insight and an understanding of which portfolios are better - and potentially more lucrative – investments. Click here to download this eBook.
If you find this article informative and useful, please help me share the information. I try to write about topics that are interesting and have the potential to be of investment value. It is not easy to find stories that fit those parameters. If you or your organisation sees the benefit of what Samso is trying to achieve and has a need to share your journey, please get in touch with me at noel.ong@samso.com.au.
Samso is a trusted platform that equips dedicated investors with up-to-date industry knowledge and insights from top CEOs and thought leaders. By staying informed on business advancements and market trends, investors can enhance their financial decisions through a combination of expert guidance and their own research.
Comments